In continuing efforts of improving
benzoxazepine derivatives as
an anti-breast cancer agent, a new chemical entity, benzoxazine, was
designed from scaffold morphing. Structure–activity relationship
studies revealed that H, −OMe, −CF3, and
−F were well tolerated on R1 and R2 positions
of ring A, and R2 as −CH2CH2N(CH2)4 (N-ethyl
pyrrolidine) and −CH2CH2N(CH2)5 (N-ethyl piperidine) chains on ring
D increased activities (Series B, Figure 3). 13d selected as a lead compound (IC50: 0.20 to 0.65 μM)
induces apoptosis, cell cycle arrest, and loss of mitochondrial membrane
potential in breast cancer cells. Compound 13d was formulated
into 13d–f using cyclodextrin to improve its solubility
for a pharmacokinetic, in vivo efficacy study. Both 13d and 13d–f regressed tumor growth at
concentrations of 5 and 20 mg/kg better than tamoxifen without any
mortality in a rat syngenic mammary tumor model. Collectively, our
data suggest that tyrosine-derived novel benzoxazine 13d could be a potential lead for the treatment of breast cancer and
hence deserve further in-depth studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.